2 Thermo Fisher Way
171 articles with ViewRay Incorporated
ViewRay Announces Conference Call and Webcast of First Quarter 2019 Financial Results to be Held After Market on May 2, 2019
ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2019 financial results.
ViewRay Announces Conference Call and Webcast of Fourth Quarter and Full Year 2018 Financial Results to be Held After Market on March 14, 2019
ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2018 financial results.
Siteman Cancer Center Advances Precision Cancer Care through Presentations, Peer-Reviewed Publications and Pioneering Clinical Experience on its MRIdian Systems
ViewRay, Inc. today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2018. The preliminary results have not been audited and are subject to change.
ViewRay, Inc. announced that the Company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California. Scott Drake, President and CEO, is scheduled to present at 8:30 a.m. Pacific Time on Wednesday, January 9, 2019.
Mr. Fuchs has over 18 years of experience in leading human resources.
ViewRay, Inc. (NASDAQ: VRAY) announced today that company management is scheduled to participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare Conference in New York, NY.
ViewRay, Inc. today announced financial results for the third quarter ended September 30, 2018.
ViewRay signs agreement with GenesisCare to bring the first MRIdian MRI-guided radiotherapy systems to the UK
New agreement expands access to precision radiotherapy for people with cancer
Real-Time Adaptive Radiotherapy Capabilities of ViewRay's MRIdian Highlighted at Investor & Analyst Meeting at ASTRO 2018
Leading Oncologists Provide Practical, Clinical, and Economic Rationale for MRIdian MRI-Guided Radiation Therapy in the Treatment of Cancer
ViewRay Announces Conference Call and Webcast of Third Quarter 2018 Financial Results to be Held After Market on November 8, 2018
ViewRay will hold a conference call on Thursday November 8, 2018 at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results.
ASTRO 2018 Presentations to Feature Unique Capabilities and Clinical Outcomes of ViewRay's MRIdian Next Generation Cancer Care
Presentations to Highlight Clinical Value of World's Only FDA-Cleared MRI-guided Radiotherapy System
ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will hold a meeting for investors and analysts on Monday, October 22, 2018, during the annual meeting of the American Society for Radiation Oncology (ASTRO) in San Antonio, TX.
Mr. Alecxih to Lead Company's Commercial Expansion
MRI-Guided Radiation Therapy Aims to Prolong Survival and Reduce Complications for the Most Challenging Cancers
Leading Radiation Oncology Experts Convene to Discuss Future of Radiation Therapy
ViewRay, Inc. announced today that members of the executive management team are scheduled to present at the Cantor Global Healthcare Conference in New York, NY.
ViewRay, Inc. today announced grants of stock options and restricted stock units to several new officers and employees.
ViewRay Incorporated (NASDAQ: VRAY) announced today that members of the executive management team are scheduled to participate in two upcoming investor conferences.
ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of 18,648,649 shares of Its Common Stock
ViewRay, Inc. announced the completion of its previously announced underwritten public offering of 18,648,649 shares of common stock at a price to the public of $9.25 per share
ViewRay, Inc. announced the pricing of an underwritten public offering of 16,216,217 shares of common stock at a price to the public of $9.25 per share